How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/infection-due-to-pseudomonas-aeruginosa.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Infection due to Pseudomonas aeruginosa — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Infection due to Pseudomonas aeruginosa (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Infection due to Pseudomonas aeruginosa, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Merrem	Meropenem	Pfizer	meropenem		1996-01-01
Maxipime	CEFEPIME	Baxter	Cephalosporin Antibacterial		1996-01-01
Maxipime	Cefepime Hydrochloride	Baxter	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Merrem	Merrem	National Institutes of Health Clinical Center (CC)		Beta-lactamase, Beta-lactamase NDM-1, Beta-lactamase class B VIM-2
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Infection due to Pseudomonas aeruginosa
Baxter · 2 drugs in Infection due to Pseudomonas aeruginosa
Merck & Co. · 2 drugs in Infection due to Pseudomonas aeruginosa
Bristol-Myers Squibb · 2 drugs in Infection due to Pseudomonas aeruginosa
University Hospital Tuebingen · 1 drug in Infection due to Pseudomonas aeruginosa
Assistance Publique - Hôpitaux de Paris · 1 drug in Infection due to Pseudomonas aeruginosa
National Institutes of Health Clinical Center (CC) · 1 drug in Infection due to Pseudomonas aeruginosa
Pfizer · 1 drug in Infection due to Pseudomonas aeruginosa
Poitiers University Hospital · 1 drug in Infection due to Pseudomonas aeruginosa
Bayer AG · 1 drug in Infection due to Pseudomonas aeruginosa

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Infection due to Pseudomonas aeruginosa:

Cite this brief

Drug Landscape (2026). Infection due to Pseudomonas aeruginosa — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infection-due-to-pseudomonas-aeruginosa. Accessed 2026-06-10.

Infection due to Pseudomonas aeruginosa full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing